The incidence of cerebral palsy among children conceived through in vitro fertilization (IVF) has been halved over the past two decades, although the risk of cerebral palsy remains higher than children who are conceived naturally, according to a Nordic study presented at ESHRE 2020 Meeting.
The benefit of using dolutegravir for HIV treatment in pregnant women outweighs the risk. This is the message delivered by two studies presented at the 23rd International AIDS Conference, which have shown that the drug induces rapid viral suppression and brings a slight but nonsignificant risk of neural tube defects (NTDs) compared with other antiretrovirals.
Patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) do not have a higher risk of major adverse cardiovascular events (MACE) with ertugliflozin, according to results of the phase III VERTIS CV* trial.
Thrombotic complications are rife among in-hospital patients with COVID-19, with patients in the ICU particularly at risk compared with those in the general wards, a study released at the ISTH 2020 Meeting has shown.
De-escalating the BEACOPPescalated* regimen through a PET-driven strategy may reduce the risk of acute premature ovarian insufficiency (POI) in women with newly diagnosed advanced Hodgkin lymphoma (HL), subanalysis results of the phase III AHL2011 trial have shown.
At a lower dose, the single-pill drug that combines elvitegravir (EVG), cobicistat, emtricitabine, and tenofovir alafenamide (TAF) has an acceptable safety profile and maintains virological suppression in HIV-infected children, according to the results of a single-arm, open label trial.
Among patients with cancer who develop COVID-19, progressive disease and a higher ECOG* performance status (PS) are tied to an increased risk of mortality, according to early results ascertained from the COVID-19 and Cancer Consortium (CCC19) registry.
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.